Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jul;74(2):300–308. doi: 10.1038/bjc.1996.357

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.

A Howell 1, D J DeFriend 1, J F Robertson 1, R W Blamey 1, L Anderson 1, E Anderson 1, F A Sutcliffe 1, P Walton 1
PMCID: PMC2074590  PMID: 8688341

Abstract

We have assessed the pharmacokinetics, pharmacological and anti-tumour effects of the specific steroidal anti-oestrogen ICI 182780 in 19 patients with advanced breast cancer resistant to tamoxifen. The agent was administered as a monthly depot intramuscular injection. Peak levels of ICI 182780 occurred a median of 8-9 days after dosing and then declined but were above the projected therapeutic threshold at day 28. Cmax during the first month was 10.5 ng/ml-1 and during the sixth month was 12.6 ng ml-1. The AUCs were 140.5 and 206.8 ng day ml-1 on the first and sixth month of dosing respectively, suggesting some drug accumulation. Luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels rose after withdrawal of tamoxifen and then plateaued, suggesting no effect of ICI 182780 on the pituitary-hypothalamic axis. There were no significant changes in serum levels of prolactin, sex hormone-binding globulin (SHBG) or lipids. Side-effects were infrequent. Hot-flushes and sweats were not induced and there was no apparent effect of treatment upon the endometrium or vagina. Thirteen (69%) patients responded (seven had partial responses and six showed "no change' responses) to ICI 182780, after progression on tamoxifen, for a median duration of 25 months. Thus ICI 182780, given by monthly depot injection, and at the drug levels described, is an active second-line anti-oestrogen without apparent negative effects on the liver, brain or genital tract and warrants further evaluation in patients with advanced breast cancer.

Full text

PDF
300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertelli G., Pronzato P., Amoroso D., Cusimano M. P., Conte P. F., Montagna G., Bertolini S., Rosso R. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988 Dec;12(3):307–310. doi: 10.1007/BF01811244. [DOI] [PubMed] [Google Scholar]
  2. Clarke R. B., Laidlaw I. J., Jones L. J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer. 1993 Mar;67(3):606–611. doi: 10.1038/bjc.1993.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohen I., Rosen D. J., Tepper R., Cordoba M., Shapira Y., Altaras M. M., Yigael D., Beyth Y. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med. 1993 May;12(5):275–280. doi: 10.7863/jum.1993.12.5.275. [DOI] [PubMed] [Google Scholar]
  4. Cole M. P., Jones C. T., Todd I. D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971 Jun;25(2):270–275. doi: 10.1038/bjc.1971.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coopman P., Garcia M., Brünner N., Derocq D., Clarke R., Rochefort H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. Int J Cancer. 1994 Jan 15;56(2):295–300. doi: 10.1002/ijc.2910560225. [DOI] [PubMed] [Google Scholar]
  6. Cruz J. M., Muss H. B., Brockschmidt J. K., Evans G. W. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Semin Oncol. 1990 Dec;17(6 Suppl 9):63–67. [PubMed] [Google Scholar]
  7. Dauvois S., Danielian P. S., White R., Parker M. G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A. 1992 May 1;89(9):4037–4041. doi: 10.1073/pnas.89.9.4037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. DeFriend D. J., Howell A., Nicholson R. I., Anderson E., Dowsett M., Mansel R. E., Blamey R. W., Bundred N. J., Robertson J. F., Saunders C. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994 Jan 15;54(2):408–414. [PubMed] [Google Scholar]
  9. Dukes M., Waterton J. C., Wakeling A. E. Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol. 1993 Aug;138(2):203–210. doi: 10.1677/joe.0.1380203. [DOI] [PubMed] [Google Scholar]
  10. Fawell S. E., White R., Hoare S., Sydenham M., Page M., Parker M. G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6883–6887. doi: 10.1073/pnas.87.17.6883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Silfverswärd C., Skoog L., Somell A., Theve T., Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989 Jan 21;1(8630):117–120. doi: 10.1016/s0140-6736(89)91141-0. [DOI] [PubMed] [Google Scholar]
  12. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  13. Gottardis M. M., Jiang S. Y., Jeng M. H., Jordan V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989 Aug 1;49(15):4090–4093. [PubMed] [Google Scholar]
  14. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995 Jan 7;345(8941):29–30. doi: 10.1016/s0140-6736(95)91156-1. [DOI] [PubMed] [Google Scholar]
  15. Howell A., Dodwell D. J., Anderson H., Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol. 1992 Sep;3(8):611–617. doi: 10.1093/oxfordjournals.annonc.a058286. [DOI] [PubMed] [Google Scholar]
  16. Ignar-Trowbridge D. M., Nelson K. G., Bidwell M. C., Curtis S. W., Washburn T. F., McLachlan J. A., Korach K. S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4658–4662. doi: 10.1073/pnas.89.10.4658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Love R. R., Newcomb P. A., Wiebe D. A., Surawicz T. S., Jordan V. C., Carbone P. P., DeMets D. L. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990 Aug 15;82(16):1327–1332. doi: 10.1093/jnci/82.16.1327. [DOI] [PubMed] [Google Scholar]
  18. Lykkesfeldt A. E., Madsen M. W., Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res. 1994 Mar 15;54(6):1587–1595. [PubMed] [Google Scholar]
  19. Lykkesfeldt A. E., Sørensen E. K. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol. 1992;31(2):131–138. doi: 10.3109/02841869209088892. [DOI] [PubMed] [Google Scholar]
  20. Osborne C. K., Coronado E., Allred D. C., Wiebe V., DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16;83(20):1477–1482. doi: 10.1093/jnci/83.20.1477. [DOI] [PubMed] [Google Scholar]
  21. Pavlik E. J., Nelson K., Srinivasan S., Powell D. E., Kenady D. E., DePriest P. D., Gallion H. H., van Nagell J. R., Jr Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res. 1992 Aug 1;52(15):4106–4112. [PubMed] [Google Scholar]
  22. Power R. F., Mani S. K., Codina J., Conneely O. M., O'Malley B. W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991 Dec 13;254(5038):1636–1639. doi: 10.1126/science.1749936. [DOI] [PubMed] [Google Scholar]
  23. Reddy K. B., Mangold G. L., Tandon A. K., Yoneda T., Mundy G. R., Zilberstein A., Osborne C. K. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 1;52(13):3636–3641. [PubMed] [Google Scholar]
  24. Robertson J. F., Ellis I. O., Nicholson R. I., Robins A., Bell J., Blamey R. W. Cellular effects of tamoxifen in primary breast cancer. Breast Cancer Res Treat. 1992 Jan;20(2):117–123. doi: 10.1007/BF01834641. [DOI] [PubMed] [Google Scholar]
  25. Robertson J. F., Williams M. R., Todd J., Nicholson R. I., Morgan D. A., Blamey R. W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol. 1989 Mar;25(3):469–475. doi: 10.1016/0277-5379(89)90259-9. [DOI] [PubMed] [Google Scholar]
  26. Sakai F., Cheix F., Clavel M., Colon J., Mayer M., Pommatau E., Saez S. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol. 1978 Feb;76(2):219–226. doi: 10.1677/joe.0.0760219. [DOI] [PubMed] [Google Scholar]
  27. Simon W. E., Albrecht M., Trams G., Dietel M., Hölzel F. In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J Natl Cancer Inst. 1984 Aug;73(2):313–321. doi: 10.1093/jnci/73.2.313. [DOI] [PubMed] [Google Scholar]
  28. Stewart A. J., Westley B. R., May F. E. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer. 1992 Oct;66(4):640–648. doi: 10.1038/bjc.1992.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Turken S., Siris E., Seldin D., Flaster E., Hyman G., Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst. 1989 Jul 19;81(14):1086–1088. doi: 10.1093/jnci/81.14.1086. [DOI] [PubMed] [Google Scholar]
  30. Vogel C. L., Shemano I., Schoenfelder J., Gams R. A., Green M. R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993 Feb;11(2):345–350. doi: 10.1200/JCO.1993.11.2.345. [DOI] [PubMed] [Google Scholar]
  31. Wakeling A. E., Bowler J. Novel antioestrogens without partial agonist activity. J Steroid Biochem. 1988 Oct;31(4B):645–653. doi: 10.1016/0022-4731(88)90014-3. [DOI] [PubMed] [Google Scholar]
  32. Wakeling A. E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867–3873. [PubMed] [Google Scholar]
  33. Wakeling A. E., Newboult E., Peters S. W. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol. 1989 May;2(3):225–234. doi: 10.1677/jme.0.0020225. [DOI] [PubMed] [Google Scholar]
  34. Willemse P. H., van der Ploeg E., Sleijfer D. T., Tjabbes T., van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer. 1990 Mar;26(3):337–343. doi: 10.1016/0277-5379(90)90231-h. [DOI] [PubMed] [Google Scholar]
  35. Willis K. J., London D. R., Ward H. W., Butt W. R., Lynch S. S., Rudd B. T. Recurrent breast cancer treated with the antioestrogen tamoxifen: correlation between hormonal changes and clinical course. Br Med J. 1977 Feb 12;1(6058):425–428. doi: 10.1136/bmj.1.6058.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wolf D. M., Langan-Fahey S. M., Parker C. J., McCague R., Jordan V. C. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst. 1993 May 19;85(10):806–812. doi: 10.1093/jnci/85.10.806. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES